AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps ...

Sinus infections, or sinusitis, occur when a virus of bacteria enters the sinuses. Read on for a list of common symptoms and treatments.